SCHEMBL4275574

SCHEMBL4275574

O=C(O)CN1CCC2(C=Cc3ccccc3O2)CC1c1cc(F)c(O)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.39
HTR2C P28335 3/20 0.37
HTR2B P41595 1/20 0.37
ADRA1D P25100 1/20 0.37
ADRA1A P35348 1/20 0.37
ADRA1B P35368 1/20 0.37
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
GRIN2B Q13224 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279349 0.86 SCD (0.41) SCDHTR2CHTR2BADRA1DADRA1A
SCHEMBL7400617 0.73 HTR2C (0.49) SCDHTR2CHTR2BADRA1DADRA1A
Hydrochloric Acid SCHEMBL4269341 0.73 ADRA1D (0.54) SCDHTR2CHTR2BADRA1DADRA1A
SCHEMBL12481728 0.68 HTR2C (0.57) SCDHTR2CHTR2BADRA1DADRA1A
SCHEMBL7370885 0.64 HTR2C (0.62) SCDHTR2CHTR2BADRA1DADRA1A
Bromide SCHEMBL4277717 0.64 OPRD1 (0.52)
SCHEMBL3709748 0.64 HTR2C (0.55) SCDHTR2CHTR2BADRA1DADRA1A
SCHEMBL4275257 0.62 HDAC3 (0.58) HTR2CHTR2BADRA1DADRA1AADRA1B
SCHEMBL3413391 0.62 HTR2C (0.62) SCDHTR2CHTR2BADRA1DADRA1A
SCHEMBL1912703 0.61 HTR2C (0.51) SCDHTR2CHTR2BADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507824-B2 Spiro(2H-1benzopyran-2,4′-piperidine) derivates as glycine transport inhibitors N.V. ORGANON (NL) 2009-03-24 US disclosed
EP-1232160-B1 SPIRO(2H-1-BENZOPYRAN-2,4'-PIPERIDINE)DERIVATES AS GLYCINE TRANSPORT INHIBITORS ORGANON NV (NL) 2008-06-18 EP disclosed
US-20040029904-A1 Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors MERCK SHARP & DOHME B.V. (NL) 2004-02-12 US disclosed
US-6645973-B1 Heterocyclic amines such as 1-carboxymethyl-4-(4-chlorophenyl) spiro(2H-1-benzopyran-2,4'-piperidine)hydrochloride used for therapy of nervous system disorders; Alzheimer's, Parkinson's and Huntington's disease AKZO NOBEL (NL) 2003-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029904-A1 Spiro(2H-1benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors SLC6A7, SLC1A2, SLC6A1 SCD 3902/4885HTR2C 585/4885HTR2B 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.